Category: Biolase Technology Inc.
Biolase shares tank after the medical device company reports gaping 3rd-quarter losses and sacks its sales vice presidents, saying it will court a potential acquirer.
Biolase and Auris Surgical Robotics ink a deal to co-develop a cataract-removal ophthalmological robot.
Biolase (NSDQ:BIOL) and Auris Surgical Robotics said they've inked a deal to collaborate on developing a cataract-removal ophthalmologic robot.
A group of Biolase shareholders are suing in a class action lawsuit accusing company directors of lying about its financial struggles.
Biolase (NSDQ:BLTI) is facing a lawsuit brought by shareholders accusing the company of hiding problems by lying on quarterly earnings reports. The lawsuit claims Biolase and its directors concealed liquidity and solvency issues as well as under-performing sales.
Martha Shadan, a former executive for the likes of Zimmer and Covidien, will take the reins at young orthotics company Rotation Medical.
Minnesota-based orthotics company Rotation Medical appointed Martha Shadan as the new president & CEO.
Second Sight Medical registers for a $10 million funding round to back its Argus II 'bionic eye' retinal implant.
Second Sight Medical is hoping to raise $10.5 million, according to a regulatory filing, as it brings its "bionic eye" Argus II retinal implant to the U.S. market.
The device, comprised of an eyeglass-mounted camera and an electrical stimulator implanted in the eye, works by converting video images captured by a miniature camera housed in the patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes on the surface of the retina.
Two heads are better than 1 at Mindray Medical, which appointed chief strategic officer Cheng Minghe as co-CEO alongside chief Li Xiting.
Mindray Medical (NYSE:MR) chief Li Xiting will share the corner office, so to speak, with new co-CEO Cheng Minghe, who takes the new title in addition to continuing as the company's chief strategic officer.
Cheng is one of the founders of the Shenzhen, China-based company, and has worked in various roles since 1991.
Biolase CEO Federico Pignatelli, who made waves with his commitment to a $1 salary, denies rumors that he is stepping down.
Biolase (NSDQ:BLTI) issued a message to concerned investors, quashing rumors of CEO Federico Pignatelli's imminent departure and asserting his continued leadership of the dental laser company.